# ORCHARD (NCT03944772)

> Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03944772
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Osimertinib; Savolitinib; Gefitinib; Necitumumab; Durvalumab; Carboplatin; Pemetrexed; Alectinib; Selpercatinib; Selumetinib; Etoposide; Cisplatin; Datopotamab deruxtecan
- Enrollment: 247
- Primary outcome: Objective response rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=orchard-nct03944772